TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03722043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Program
Description: Parents will participate in a 5-week parenting program designed to uniquely work with veteran families. The program will target the following areas: mindful parenting strategies, emotional regulation, positive discipline, positive parenting/attachment, and sleep.
Study: NCT03288935

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TICM
Description: The TICM will be designed to include the seven domains of trauma-informed care articulated by SAMHSA (2014): 1) early screening and comprehensive assessment; 2) consumer driven care and services; 3) trauma-informed, responsive and educated workforce; 4) emerging and evidence-informed best practices; 5) safe and secure environments; 6) trauma-informed community partnerships; and 7) a performance monitoring system. The trained agency case managers and staff will provide the TICM to 50 newly resettled refugees during their regular R\&P service period (i.e., 60 days).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TICM
Description: The TICM will be designed to include the seven domains of trauma-informed care articulated by SAMHSA (2014): 1) early screening and comprehensive assessment; 2) consumer driven care and services; 3) trauma-informed, responsive and educated workforce; 4) emerging and evidence-informed best practices; 5) safe and secure environments; 6) trauma-informed community partnerships; and 7) a performance monitoring system. The trained agency case managers and staff will provide the TICM to 50 newly resettled refugees during their regular R\&P service period (i.e., 60 days).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TICO
Description: The community-based TICO will be based on the Im's CHW that comprises 8 sessions (2 hour per session), co-facilitated by trained refugee peer mentors and community service providers. The TICO sessions will include interactive sessions on healthy eating, healthy body and healthy mind, acculturation \& resettlement stress, understanding trauma and stress, healthy coping, helping others, and community building.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TICO
Description: The community-based TICO will be based on the Im's CHW that comprises 8 sessions (2 hour per session), co-facilitated by trained refugee peer mentors and community service providers. The TICO sessions will include interactive sessions on healthy eating, healthy body and healthy mind, acculturation \& resettlement stress, understanding trauma and stress, healthy coping, helping others, and community building.
Study: NCT04070027

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Total hip arthroplasty following standard procedures.
Study: NCT03467373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m\^2 administered IV on Day 1 of each 21-day cycle
Study: NCT01608984

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning (RIPC)
Description: 3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion.~The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. In the CABG-arms, during extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Coronary artery bypass grafting (CABG) without remote ischemic preconditioning protocol
Description: The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
Study: NCT03467373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m\^2 administered by IV push on Day 1 of each 21-day cycle with a recommended cap of 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m\^2 administered by IV push on Day 1 of each 21-day cycle with a recommended cap of 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg/day orally on Days 1-5 (prednisone on Day 1 may be administered IV, with the remaining doses on Days 2-5 to be administered orally) of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg/day orally on Days 1-5 (prednisone on Day 1 may be administered IV, with the remaining doses on Days 2-5 to be administered orally) of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 100 mg/day orally on Days 1-5 (prednisone on Day 1 may be administered IV, with the remaining doses on Days 2-5 to be administered orally) of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Polatuzumab vedotin 1.8 mg/kg administered IV on Day 1 of each 21-day cycle
Study: NCT04070027

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Resistance Training
Description: Progressive resistance training based on available evidence on patients with hip osteoarthritis and designed in accordance with the American College of Sports Medicine (ACSM) recommendations for progression models in resistance training aiming at inducing muscle hypertrophy and increasing muscle strength and power.
Study: NCT01608984

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Off-pump Coronary artery bypass surgery without remote ischemic preconditioning
Description: The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required.
Study: NCT00981838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab (375 mg/m2) will be given as a single intravenous infusion after reconstitution in normal saline to a concentration of 1 mg/ml given though a 0.22 micron in line filter. The initial infusion rate will be 1 ml/kg/h and will be progressively increased up to 4 ml/kg/h according to drug tolerability. Pre-medication with steroids and/or antihistaminic agents will be done according to per-center's practice.Rituximab administration will be repeated in those patients \> 5 B cells/mm3 in the peripheral blood on the day after first Rituximab administration.
Study: NCT02275403

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 10 x weekly sessions (40 minutes per session) of acupuncture by a trained therapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication taken to manage the symptom burden of CIPN
Description: Standard of care medication to manage CIPN symptoms, as determined by a clinician in accordance with local trust policy. The standard care for CIPN includes a variety of oral medications to manage the altered sensations caused by damage to the peripheral nerves. These oral medications include, but are not limited to; Gabapentin, Amitriptyline and Pregabalin. In addition, medicated creams and gels may be used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication taken to manage the symptom burden of CIPN
Description: Standard of care medication to manage CIPN symptoms, as determined by a clinician in accordance with local trust policy. The standard care for CIPN includes a variety of oral medications to manage the altered sensations caused by damage to the peripheral nerves. These oral medications include, but are not limited to; Gabapentin, Amitriptyline and Pregabalin. In addition, medicated creams and gels may be used.
Study: NCT04254315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group based cognitive therapy
Description: Patients are informed about the Optima program in the inclusion interview, and patients are participating in groups of maximum 4 persons. Each of the 5 session has a duration of 1,5 - 2 hours.~The psychologist have developed the content of each session, with attention to thoughts and feelings regarding the current situation after a heart-condition, and the effects on life conditions. Patients get the tools to overcoming the difficulties, they experience, f.x. anxiety and stress.~When other hospitals are joining the Optima project, the project nurse and psychologist are training the hospital staff as well as supervising.
Study: NCT01339026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix
Description: Clopidogrel (Plavix) Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.
Study: NCT03517488

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb20717
Description: Monoclonal bispecific antibody
Study: NCT03142061

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy
Description: Bleomycin plus local electroporation of cutan accessible tumor tissue in patients with advanced inoperable vulva carcinoma
Study: NCT03252184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy - 1
Description: In the phase 1, the low level laser therapy will be performed with the Fluence device (HTM, Brasil) and the probe from the same manufacturer. For the interventions in groups G1, G2 and G3 (photobiomodulation) will be used, respectively, the energy doses of 18J, 36J and 54J. A 658nm wavelength with an output power of 10mW will be used. Group 4 intervention (placebo photobiomodulation) will be performed with the application of the device turned off. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level laser therapy - 1
Description: In the phase 1, the low level laser therapy will be performed with the Fluence device (HTM, Brasil) and the probe from the same manufacturer. For the interventions in groups G1, G2 and G3 (photobiomodulation) will be used, respectively, the energy doses of 18J, 36J and 54J. A 658nm wavelength with an output power of 10mW will be used. Group 4 intervention (placebo photobiomodulation) will be performed with the application of the device turned off. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiomodulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser probe will be placed in direct contact with the skin.
Study: NCT03602339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoterate (Dotarem/Clariscan)
Description: Patients received a single dose of 0.5 molar gadoterate (0.1 mmol per kg body weight) intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoterate (Dotarem/Clariscan)
Description: Patients received a single dose of 0.5 molar gadoterate (0.1 mmol per kg body weight) intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist/Gadovist, BAY86-4875)
Description: Patients received a single dose of 1.0 molar BAY86-4875 (0.075 mmol per kg body weight) intravenously.
Study: NCT01438060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole (BMS-337039)
Description: Acute Phase: Oral, Tablets (1 and 5 mg), Week 1-2: 2 mg, Week 3-4: 2 - 5 mg, Week 5-6: 2 - 10 mg, Weeks 7-10: 2 - 15 mg, Once daily, 10 weeks~Extension Phase: Oral, Tablets (1 and 5 mg), Week 11: 2 mg, Weeks 12-13: 2 - 5 mg, Weeks 14-15: 2 - 10 mg, Weeks 16-140: 2 - 15 mg, Once daily, 130 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Acute Phase: Oral, Tablets, 0 mg, Once daily, 10 Weeks
Study: NCT04022122

Intervention type: PROCEDURE
Intervention: Usual Care follow-up in a heart failure program.
Description: Standard follow-up involves hospital and primary care for HF patients. In this context, physicians and nurses experienced in the care and management of HF direct care. HF care is based on 1) active detection of newly admitted HF patients, 2) planned educational interventions to improve self-care, 3) completion of a comprehensive psychosocial assessment of patients and caregivers, 4) discharge planning and home transition coordination involving the hospital HF team and Primary Care teams, 5) structured and planned evidence-based follow-up shortly after discharge from hospital.
Study: NCT00189553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: 30 mg/m² every 4 weeks during 6 cycles or until progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 every 3/4 weeks during 6 cycles or until progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 5 every 3/4 weeks during 6 cycles or until progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 175 mg/m² at day 1 every 3 weeks during 6 cycles or until progression
Study: NCT00308906

Intervention type: DRUG
Intervention: aminoglycoside
Description: Aminoglycosides will be administered and monitored as part of the routine standard of care for the subject.

Intervention type: DRUG
Intervention: aminoglycoside
Description: Aminoglycosides will be administered and monitored as part of the routine standard of care for the subject.

Intervention type: DRUG
Intervention: aminoglycoside
Description: Aminoglycosides will be administered and monitored as part of the routine standard of care for the subject.
Study: NCT04157205

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non-invasive ECG imaging - CardioInsight test
Description: 1. Consent session~2. Fitting of ECGi vest and CT scan of the chest~3. Supervised exercise test and Valsalva maneuvre~4. Programmed stimulation via ICD (selected participants)~5. Blood tests - genetics
Study: NCT03317067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure
Study: NCT00396162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: probiotic containing L.rhamnosus R0011 strain
Description: 500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill
Study: NCT01866124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash transfer
Description: Recipient of transfers Mothers are the primary recipient of the CT. Cash is transferred using mobile phone credits that can be cashed at specific cash points provided by a telecom company.
Study: NCT04138251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: oral administration of Empagliflozin
Study: NCT00868998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine, docetaxel, and capecitabine
Description: Day 1-14: Capecitabine 600 mg/m2/day (maximum dose 2000 mg/m2/day total divided into BID PO doses) Day 4 and 11: Gemcitabine 600 mg/m2 IV over 60 mins Day 4 and 11: Docetaxel 30 mg/m2 IV over 60 mins preceded by 12 mg dexamethasone IV or PO or 4 mg if diabetic
Study: NCT03264092

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound guided fine needle biopsy
Description: Using the echoendoscope the lesion is identified and the needle is inserted in it to obtain a biopsy also under sonographic guidance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound guided fine needle biopsy
Description: Using the echoendoscope the lesion is identified and the needle is inserted in it to obtain a biopsy also under sonographic guidance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound guided fine needle biopsy
Description: Using the echoendoscope the lesion is identified and the needle is inserted in it to obtain a biopsy also under sonographic guidance
Study: NCT04584541

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood tests
Description: Memory T and B cell response assessment Humoral response assessment (Specific anti-Sars-Cov-2 antibodies characterization)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood tests
Description: Memory T and B cell response assessment Humoral response assessment (Specific anti-Sars-Cov-2 antibodies characterization)

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nasopharyngeal swabs
Description: SarS-Cov-2 viral load assessment

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nasopharyngeal swabs
Description: SarS-Cov-2 viral load assessment

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stools
Description: SarS-Cov-2 viral load assessment

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stools
Description: SarS-Cov-2 viral load assessment
Study: NCT02604641

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Subjects will take 5 mL of placebo syrup (0 mg CoQ10/day) once per day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Quvital LD group
Description: Subjects will take 5 mL of LD syrup (50 mg CoQ10/day) once per day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Quvital HD group
Description: Subjects will take 5 mL of LD syrup (150 mg CoQ10/day) once per day for 12 weeks.
Study: NCT03639077

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allograft bone alone
Description: The subject will receive an allograft as graft material of choice for sinus augmentation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allograft and xenograft mixture
Description: The subjects will receive a mixture of allograft and anorganic bovine bone xenograft as graft material of choice for sinus augmentation
Study: NCT01344031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt Inhibitor MK2206
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT05458726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib or chemotherapy

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Osimertinib
Description: Osimertinib or chemotherapy
Study: NCT03403569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptolide Wilfordii
Description: In addition to appropriate ART, Triptolide Wilfordii will be given to patients in the experimental group at a dosage of 20mg three times a day per os for 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: In addition to appropriate ART, placebo oral tablets will be given to patients in the experimental group at a dosage of 2 pills three times a day per os for 12 months.
Study: NCT04112472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EYESTAR 900
Description: EYESTAR 900 is an optical biometry device used to create a geometrical representation of the eye by means of optical interferometry. The intervention are optical, non-contact examinations with the investigational device EYESTAR 900 and comparative device(s). Results of the examinations serve to compare the performance data of the investigational device with those of the comparative devices.
Study: NCT03385057

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Grape-flavored ibuprofen 100mg/5mL (Leader®) will be dispensed. Ibuprofen will be dosed at 10mg/kg (max dose 600mg) QID (roughly Q6 hours, however we left dosing QID to allow for some flexibility in the dosing schedule to accommodate patient sleeping schedules). The pharmacy will manipulate the volume of each medication using Ora Blend suspension so that for each child, weight-based dosing of each medication will be equivalent in volume. The first dose of study medication will be dispensed 4 hours after the preoperative acetaminophen dose. Thereafter, medication will be dosed QID (or roughly 6 hours apart). Surgeons, nursing staff, and patients and their families will be blinded regarding the type of medication administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Grape-flavored acetaminophen 160mg/5mL (Leader®) will be dispensed based upon the arm to which each participant has been randomized. Acetaminophen at 15mg/kg (max dose 650mg), dosing will be QID (roughly Q6 hours, however we left dosing QID to allow for some flexibility in the dosing schedule to accommodate patient sleeping schedules). The pharmacy will manipulate the volume of each medication using Ora Blend suspension so that for each child, weight-based dosing of each medication will be equivalent in volume. The first dose of study medication will be dispensed 4 hours after the preoperative acetaminophen dose. Thereafter, medication will be dosed QID (or roughly 6 hours apart). Surgeons, nursing staff, and patients and their families will be blinded regarding the type of medication administered.
Study: NCT00739635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neramexane mesylate
Description: Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind treatment period of 17 weeks placebo